Dividend King Growth Giant: J&J Faces Lilly Challenge
Johnson & Johnson and Eli Lilly reported contrasting Q1 2026 results, pitting a durable, dividend-focused giant again...
Determine which index fund delivers stronger rolling returns using straightforward comparisons and key performance signals.
28,161 articlesJohnson & Johnson and Eli Lilly reported contrasting Q1 2026 results, pitting a durable, dividend-focused giant again...
The Moana live-action remake opened to mixed signals: a top domestic ranking but weak sales that raise questions abou...
Private equity stocks have fallen about 30%-40% over the last three months, driven by macro pressures and liquidity c...
Meta is betting big on subscriptions with Meta One to pair recurring revenue with AI capability. The thing investors ...
When a stock plunges, it’s easy to blame the hype. This week, planet labs stock plummeting has investors weighing ear...
Public spaces near Hoboken Terminal have seen a troubling spike in phone-based scams. This guide breaks down how the ...
When a company’s CFO sells shares, investors want to know if it’s a red flag or routine planning. This analysis uses ...
Veteran market commentator Jim Cramer signaled a shift to caution, saying funds are drying up for big tech deals. The...
SpaceX may steal headlines, but the real action for investors is in the earnings reports of BlackSky, Redwire, and Ro...
Broadcom is shifting from a broad tech portfolio to a focused AI chip powerhouse. If the company can turn custom AI c...
A landmark portfolio reshuffle puts Alphabet ahead of Berkshire's long-time Coca-Cola cornerstone. This analysis expl...
This guide helps investors decode Workiva's 2025 earnings landscape. Learn which metrics matter, how to read manageme...